Knowledge at the heart of leadership
  Register for career opportunities in the Oslo Cluster

Oslo Cancer Cluster - Norway

Oslo, Norway is home to the emerging Oslo Cancer Cluster, a growing cluster with a host of exciting companies targeting the oncology therapeutics and diagnostics marketplace. These companies include, Nordic Nanovector, Lytix BioPharm, Targovax and Ultimovacs.

The Oslo Cancer Cluster has big ambitions to create a global cluster comprised of world-leading experts in cancer drug development and diagnostics and wishes to attract this competence.

With a brand new innovation centre to be launched in 2015, this is an exciting time for this biotech cluster and the companies in it. Liftstream has taken time to profile the cluster through interviews with the Oslo Cancer Cluster leadership, as well as CEO’s of some of the cluster’s companies.

Oslo, Norway is home to the emerging Oslo Cancer Cluster, a growing cluster with a host of exciting companies targeting the oncology therapeutics and diagnostics marketplace. These companies include, Nordic Nanovector, Lytix BioPharm, Targovax and Ultimovacs.

For further reading please see:

The Oslo Cancer Cluster has big ambitions to create a global cluster comprised of world-leading experts in cancer drug development and diagnostics and wishes to attract this competence.

With a brand new innovation centre to be launched in 2015, this is an exciting time for this biotech cluster and the companies in it. Liftstream has taken time to profile the cluster through interviews with the Oslo Cancer Cluster leadership, as well as CEO’s of some of the cluster’s companies.

Location: Oslo, Norway – Europe

Population of Oslo: 634,000

Little known fact: Oslo is the fastest growing city in Europe

Companies Research & Development
  • 64 Life Science companies
  • 9 Public Life Science companies
  • 55 Private Life Science companies 
  • IPO's 2014 - 2 (NOTC)
  • Top Life Science deal in past 12 months – Bayer purchase of Algeta for 1.79bn Euros
  • Total R&D spend in country 130m Euros
  • Total R&D spend public companies 45m Euros
  • NIH Funding: 56.4m Euros
  • Patents per capita – 14.1
Employment Therapeutic Excellence
  • Total Life Science employment in Oslo - 3,500
  • Workforce composition – Strong weighting towards Academia,early stage ventures, service companies and large pharma affiliates
  • Top selling cancer drug developed in the cluster – Xofigo (Algeta/Bayer) – Q2 32.6m Euros
  • Therapeutic Focus – Oncology, immunotherapy, vaccines
  • Top 3 Selling Drugs in the Country – 1. Humira 2. Enbrel 3. Remicade

Cluster talent score (availability of local leadership experience in biotech) – 4/10

Gender Diversity Score (leadership opportunities for women) – 8.5/10

Cluster Executive Competence – Local talent market is underpopulated, need to bring in talent from outside of Oslo and Norway.





Facts about Oslo Cluster
  • 64 Life Science companies
  • Strong therapeutic focus towards immunotherapy and oncology
  • Total R&D spend in excess of 130m Euros
  • 14.1 patents per capita
  • Top selling drug developed in the cluster – Xofigo (Algeta/Bayer)–Q2 32.6m Euros
Oslo Cancer Cluster - Norway Insights

Twitter

Featured content

Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: +44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap